Taking together all available clinical data on MPN, one may conclude that JAK2 inhibitors give a benefit to patients with MF, by reducing spleen size of ~ 50% in approximately 40-50% of patients and by abolishing symptoms in the vast majority of MF patients. This evidence concerns the gene JAK2 and myeloproliferative disorder.